Peripheral oxidative stress in relapsing-remitting multiple sclerosis

Clinical Biochemistry

Volumn 45, Issue 6, 2012, Pages 440-444

  Tasset, Inmaculada ^a   Agüera, Eduardo ^b   Sánchez López, Fernando ^b   Feijóo, Montserrat ^a   Giraldo, Ana I ^a   Cruz, Antonio H ^c   Gascón, Félix ^c   Túnez, Isaac ^a  

^a Universidad de Cordoba   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

Antioxidant system; Global oxidative stress; Glutathione redox system; Multiple sclerosis; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTIOXIDANT; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; INTERCELLULAR ADHESION MOLECULE 1; MYELOPEROXIDASE; SUPEROXIDE DISMUTASE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; DEOXYGUANOSINE; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXIDOREDUCTASES; PROTEIN CARBONYLATION;

EID: 84858444025     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.01.023     Document Type: Article

References (38)

1. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
2. Miller E., Mrowicka M., Malinowska K., Zolynski K., Kedziora J. Effects of the whole-body cryotherapy on a total antioxidative status and activities of some antioxidative enzymes in blood of patients with multiple sclerosis-preliminary study. J Med Invest 2010, 57:168-173.
3. van Horssen J., Witte M.E., Schreibelt G., de Vries H.E. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta 2011, 1812:141-150.
4. Ghabaee M., Jabedari B., Al E.E.N., Ghaffarpour M., Asadi F. Serum and cerebrospinal fluid antioxidant activity and lipid peroxidation in Guillain-Barre syndrome and multiple sclerosis patients. Int J Neurosci 2010, 120:301-304.
5. Witherick J., Wilkins A., Scolding N., Kemp K. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis 2010, 2011:164608.
6. Dringen R. Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal 2005, 7:1223-1233.
7. Miller E., Mrowicka M., Saluk-Juszczak J., Ireneusz M. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res 2011, 36:1012-1016.
8. Usatyuk P.V., Natarajan V. Hydroxyalkenals and oxidized phospholipids modulation of endothelial cytoskeleton, focal adhesion and adherens junction proteins in regulating endothelial barrier function. Microvasc Res 2012, 83:45-55.
9. Haider L., Fischer M.T., Frischer J.M., Bauer J., Höftberger R., Botond G., et al. Oxidative damage in multiple sclerosis lesions. Brain 2011, 134:1914-1924.
10. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
11. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
12. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478.
13. Luo S., Levine R.L. Methionine in proteins defends against oxidative stress. FASEB J 2009, 23:464-472.
14. Shimoike T., Inoguchi T., Umeda F., Nawata H., Kawano K., Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 2000, 49:1030-1035.
15. Flohe L., Gunzler W.A. Assays of glutathione peroxidase. Methods Enzymol 1984, 105:114-121.
16. Warholm M., Guthenberg C., von Bahr C., Mannervik B. Glutathione transferases from human liver. Methods Enzymol 1985, 113:499-504.
17. Tunez I., Sanchez-Lopez F., Aguera E., Fernandez-Bolanos R., Sanchez F.M., Tasset-Cuevas I. Important role of oxidative stress biomarkers in Huntington's disease. J Med Chem 2011, 54:5602-5606.
18. Ortiz G.G., Macias-Islas M.A., Pacheco-Moises F.P., Cruz-Ramos J.A., Sustersik S., Barba E.A., et al. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers 2009, 26:35-39.
19. Stavropoulou C., Zachaki S., Alexoudi A., Chatzi I., Georgakako V.N., Terzoudi G.I., et al. The C(609)T inborn polymorphism in NAD(P)H:quinone oxidoreductase 1 is associated with susceptibility to multiple sclerosis and affects the risk of development of the primary progressive form of the disease. Free Radic Biol Med 2011, 51:713-718.
20. Hadzovic-Dzuvo A., Lepara O., Valjevac A., Avdagic N., Hasic S., Kiseljakovic E., et al. Serum total antioxidant capacity in patients with multiple sclerosis. Bosn J Basic Med Sci 2011, 11:33-36.
21. Li S., Vana A.C., Ribeiro R., Zhang Y. Distinct role of nitric oxide and peroxynitrite in mediating oligodendrocyte toxicity in culture and in experimental autoimmune encephalomyelitis. Neuroscience 2011, 184:107-119.
22. Calabrese V., Bella R., Testa D., Spadaro F., Scrofini A., Rizza V., et al. Increased cerebrospinal fluid and plasma levels of ultraweak chemiluminescence are associated with changes in the thiol pool and lipid-soluble fluorescence in multiple sclerosis: the pathogenic role of oxidative stress. Drugs Exp Clin Res 1998, 24:125-131.
23. Syburra C., Passi S. Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh 1999, 71:112-115.
24. Besler H.T., Comoglu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 2003, 6:189-196.
25. Koch M., Mostert J., Arutjunyan A.V., Stepanov M., Teelken A., Heersema D., et al. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 2007, 14:529-533.
26. Fjeldstad A.S., McDaniel J., Witman M.A., Ives C.J., Zhao J., Rose J.W., et al. Vascular function and multiple sclerosis. J Neurol 2011, 258:2036-2042.
27. Castegna A., Palmieri L., Spera I., Porcelli V., Palmieri F., Fabis-Pedrini M.J., Kean R.B., et al. Oxidative stress and reduced glutamine synthetase activity in the absence of inflammation in the cortex of mice with experimental allergic encephalomyelitis. Neuroscience 2011, 185:97-105.
28. Choi I.Y., Lee S.P., Denney D.R., Lynch S.G. Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3T. Mult Scler 2011, 17:289-296.
29. Srinivasan R., Ratiney H., Hammond-Rosenbluth K.E., Pelletier D., Nelson S.J. MR spectroscopic imaging of glutathione in the white and gray matter at 7T with an application to multiple sclerosis. Magn Reson Imaging 2010, 28:163-170.
30. Calabrese V., Scapagnini G., Ravagna A., Bella R., Foresti R., Bates T.E., et al. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res 2002, 70:580-587.
31. Calabrese V., Scapagnini G., Ravagna A., Bella R., Butterfield D.A., Calvani M., et al. Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res 2003, 28:1321-1328.
32. Di Giuseppe D., Ulivelli M., Bartalini S., Battistini S., Cerase A., Passero S., et al. Regulation of redox forms of plasma thiols by albumin in multiple sclerosis after fasting and methionine loading test. Amino Acids 2010, 38:1461-1471.
33. Polidoro G., Di Ilio C., Arduini A., La Rovere G., Federici G. Superoxide dismutase, reduced glutathione and TBA-reactive products in erythrocytes of patients with multiple sclerosis. Int J Biochem 1984, 16:505-509.
34. Jensen G.E., Clausen J. Glutathione peroxidase and reductase, glucose-6-phosphate dehydrogenase and catalase activities in multiple sclerosis. J Neurol Sci 1984, 63:45-53.
35. Di Ilio C., Arduini A., Del Boccio G., La Rovere G., Federici G. Glutathione redox cycle enzyme activities in erythrocytes of multiple sclerosis patients. Clin Physiol Biochem 1986, 4:120-124.
36. Giovannoni G., Lai M., Thorpe J., Kidd D., Chamoun V., Thompson A.J., et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imagin. Neurology 1997, 48:1557-1565.
37. Acar G., Idiman F., Kirkali G., Ozakbas S., Oktay G., Cakmakci H., et al. Intrathecal sICAM-1 production in multiple sclerosis correlation with triple dose Gd-DTPA MRI enhancement and IgG index. J Neurol 2005, 252:146-150.
38. Farooqui T., Farooqui A.A. Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease. Park Dis 2011, 2011:247467.